NEW YORK (GenomeWeb News) – Pfizer Animal Health said this week that it will acquire two livestock genomics companies, Catapult Genetics and Bovigen, for an undisclosed sum.
Catapult develops and sells livestock DNA tests and gene markers and was formed through the 2006 merger of New Zealand’s Catapult Systems with Australia’s Genetic Solutions. Harahan, La.-based Bovigen is a livestock genetic test developer and distributor whose customers include Catapult.
Bovigen also participates with Texas A&M University and the National Cattlemen’s Beef Association in the Carcass Merit Project, which aims to discover and develop new genetic markers for US cattle producers.
Pfizer expects to close the acquisitions by the end of this month. It said that Catapult and Bovigen would continue to market products and services to their own customers and those of Pfizer Animal Health.
“This is a strategic initiative that places Pfizer at the forefront of livestock gene marker R&D and enhances Pfizer’s ability to offer more complete solutions to global livestock producers,” said Juan Ramon Alaix, president of Pfizer Animal Health, in a statement.